Just weeks before Sandoz completes its separation from parent firm Novartis, the company has completed a deal for worldwide rights to the Mycamine antifungal brand from Astellas.
Just a few weeks ahead of its scheduled spinoff from parent company Novartis, Sandoz has bolstered its anti-infectives business by completing a deal with Astellas for worldwide rights to the Mycamine (micafungin sodium) brand, known as Funguard in Japan.
“Through this acquisition of the leading global echinocandin, one of three major antifungal classes, Sandoz significantly reinforces its global hospital...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
